Changchun High-Tech subsidiary secures drug approvals, pursues Hong Kong listing

Changchun High & New Technology Industry Group announced that its subsidiary, Changchun JinSai Pharmaceutical Co., Ltd., has received domestic marketing approval from the National Medical Products Administration for two new drugs: recombinant follicle-stimulating hormone alpha N02 injection and Tibolone tablets. The recombinant follicle-stimulating hormone alpha N02 injection is approved for controlled ovarian stimulation to induce multiple follicle development, while Tibolone tablets are approved for treating low estrogen symptoms in postmenopausal women. These approvals are expected to enrich the company's product portfolio in women's health.

Concurrently, Changchun High & New Technology Industry Group has applied to list H-shares on the main board of the Hong Kong Stock Exchange. The application materials were submitted on September 29, 2025, and are available on the HKEXnews website. The company noted that the offering is limited to eligible overseas investors and qualified domestic investors, with the process still subject to regulatory approvals.

These developments mark a strategic push by Changchun High-Tech to expand its pharmaceutical offerings and access international capital markets. The company emphasizes that market promotion and sales of the new drugs are subject to various factors, and the H-share listing remains uncertain, urging investors to exercise caution.